What semaglutide long-term studies actually tell us

You've read the headline figure. Here is what came after it.

You probably found the 15% average weight-loss number from STEP 1 fairly quickly. What the search results often skip is that STEP 1 had a protocol-specified 68-week endpoint, and the researchers were already asking what happens next. The STEP 4 extension answered that question bluntly: participants who switched to placebo after an initial 20-week semaglutide period regained roughly two-thirds of the weight they had lost by one year later. Body weight is not a fixed state once you stop treatment. That finding did not appear to surprise clinicians, but it did change how prescribers frame these conversations.

The NICE appraisal of semaglutide (TA875) absorbed these results and concluded that treatment should run for a maximum of two years within a specialist service, with a review at six months to confirm at least 5% weight loss has occurred at the maintenance dose. Both of those conditions reflect the long-term data directly. Wegovy's ongoing benefit is real; so is its dependence on continued use. Understanding that from the outset is part of what a good consultation covers.

If you want a thorough grounding in how the Wegovy trial programme was designed and what it found, our detailed look at the Wegovy studies for weight loss covers the STEP series in full, including how each trial was structured and what the results showed, and our page on studies on Wegovy is a useful companion if you want to explore the evidence base more broadly.

What the SELECT cardiovascular trial added to the long-term picture

The STEP programme focused on weight. SELECT was a different kind of study: roughly 17,500 adults with established cardiovascular disease and a BMI of 27 or above, but without diabetes, followed for a median of around 33 months on semaglutide 2.4mg or placebo. The result was a 20% relative reduction in the composite of heart attack, stroke or cardiovascular death compared with placebo.

That figure matters for the long-term story in two ways. First, it demonstrated that semaglutide's effects on health outcomes extend meaningfully beyond the scales. Second, it gave regulators data on sustained use in a large population over a period substantially longer than the original weight-loss trials. The NHS medicines information for semaglutide reflects this broader licensed picture, which now includes a cardiovascular risk reduction indication for eligible adults alongside the weight management licence.

The side-effect profile across SELECT remained broadly consistent with what the STEP trials found: gastrointestinal effects dominated, were generally mild to moderate, and tapered with time. Serious events were not more common in the semaglutide group. That consistency across a longer observation window is one of the reasons prescribers can discuss multi-year use with reasonable confidence in the safety data, whilst still reviewing each patient regularly.

For more on how long people typically stay on treatment and what that process looks like, our page covering what Wegovy long-term use involves in practice addresses the practical side, from ongoing reviews to what sustained treatment actually looks like day to day.

The rebound question and what it means for anyone considering treatment

STEP 4 is the study most people land on when they search specifically about stopping. The regain data are clear: weight returns, and it returns substantially, when semaglutide is discontinued in people who have responded well. A 2023 follow-up analysis confirmed that metabolic markers, including blood pressure and blood glucose, also moved back toward baseline after stopping.

This is not a counsel of despair. It is biology. The same mechanisms that made treatment effective, reduced appetite signalling, slower gastric emptying, changed responses to food cues, are present because semaglutide is there. When it is not, those mechanisms revert. Framing semaglutide as a course of treatment rather than a permanent correction is the clinically honest position, and it is what the long-term study data support.

There is active research into what happens when people taper rather than stop abruptly, and into whether lifestyle changes consolidated during treatment modify the extent of rebound. Results are preliminary. The short version is: we do not yet have a reliable strategy that eliminates regain after stopping, which is why ongoing prescriber review matters throughout treatment rather than only at the start.

If you are weighing up whether the results hold over time, the evidence on whether Wegovy works long-term addresses that question directly. And if the broader question of cost over a sustained treatment period is on your mind, an honest breakdown of Wegovy pricing is worth reading alongside this.

Where the research is still developing

The honest answer on semaglutide long-term studies is that five-year data in weight management specifically is limited. SELECT gives us cardiovascular outcomes over roughly three years in a cardiovascular-disease population. Weight-focused trials with endpoints beyond 72 weeks are still running or in early publication. Longer-term safety signals, including questions occasionally raised about thyroid tissue in rodent models, have not translated into confirmed human risk, but the Black Triangle (▼) designation that Wegovy carries in the UK means the MHRA continues to collect post-marketing safety data actively.

The MHRA's Yellow Card scheme is how patients and clinicians contribute to that ongoing picture. Anyone experiencing unexpected effects on semaglutide can report directly at yellowcard.mhra.gov.uk. That is not a red flag about the medicine; it is how the safety database for any relatively new treatment stays current and credible.

What the existing long-term evidence does establish with reasonable clarity: semaglutide produces sustained weight loss during treatment, confers cardiovascular benefit in high-risk groups, carries a manageable side-effect profile over multi-year observation, and requires ongoing use to maintain its effects, a question our page on whether you can be on Wegovy long term explores in detail. A prescriber who knows your medical history is the right person to translate those population-level findings into a plan that fits you. You can start a free consultation with our prescribers to do exactly that.